Citations

Clear

7552 citation(s) found for "Ku, Matthew".

589 BASECAMP-1 is an efficient pre-screening study that identifies patients with HLA LOH and provides mutational, RNA-Seq, and microbiome data for precision logic-gated CAR T therapeutic trials
Molina, Julian R. , Spencer, Kristen , Grierson, Patrick , Ulrickson, Matthew L. , Morelli, Maria Pia , Dahiya, Saurabh , Go, William Y., Patel, Sandip Pravin , Mardiros, Armen, Tebbets, Jessica , Liechty, Kirstin B., Maloney, David G. , Welch, John P., Hecht, J. Randolph , Simeone, Diane M. , Kirtane, Kedar , Specht, Jennifer M. , Murthy, Hemant S. , Park, Jong Chul , Fakih, Marwan , Davila, Marco L , Maus, Marcela V , Ng, Eric W, Welch, John

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A672-A673

10.1136/jitc-2024-sitc2024.0589 Get It

588 EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH
Grierson, Patrick , Welling, Theodore H., Lim, Kian-Huat, Morelli, Maria Pia , Patel, Sandip Pravin , Ulrickson, Matthew L. , Kundranda, Madappa N. , Vong, Judy, Mitchell, Jasmine , Langeberg, Wendy J., Bretzlaff, William, Nikiforow, Sarah , Mardiros, Armen, Maloney, David G. , Liechty, Kirstin B., Hecht, J. Randolph , Go, William Y., Molina, Julian R. , Punekar, Salman R. , Hazim, Antonious , Simeone, Diane M. , Kirtane, Kedar , Lim, Kian-Huat , Castria, Tiago Biachi De , Maus, Marcela V , Locke, Frederick L. , Ng, Eric W

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A670-A671

10.1136/jitc-2024-sitc2024.0588 Get It

Neoadjuvant immunotherapy versus adjuvant chemotherapy in anorectal melanoma
Sassun, Richard , Sileo, Annaclara , Ng, Jyi Cheng , Violante, Tommaso , Gomaa, Ibrahim A. , Block, Matthew S. , Perry, William , Rumer, Kristen K. , Larson, David W. , Larson, David W , Violante, Tommaso , Cheng, Jyi Ng , Perry, William R , Sassun, Richard , Sileo, Annaclara , McKenna, Nicholas P.

Mayo Clinic

British Journal of Surgery | November 4, 2024 | Volume: 111 | Issue: 11 | Pages: No page available

10.1093/bjs/znae269 | PMID 39495829 Get It

Prehabilitative/rehabilitative exercise, nutrition, and psychological support for bladder cancer: A scoping review of randomized clinical trials
Parke, Sara C. , Beck, Kelsey L., Sinha, Debarshi, Ligten, Matthew J. Van, Bain, Paul , Tyson, Mark D. , Abdul‐Muhsin, Haidar , Quillen, Jaxon , Luigi, Arthur Jason De , Branstiter, Nikki L., Briggs, Logan G , Parke, Sara C , Gill, Vikram, Van Ligten, Matthew J, Quillen, Jaxon K, Dodoo, Christopher A, Psutka, Sarah P , Briggs, Logan , Sinha, Debarshi, Gill, Vikram S. , Dodoo, Christopher , Trinh, Quoc‐Dien , Psutka, Sarah P.

Mayo Clinic

Cancer | November 3, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35608 | PMID 39488730 Get It

Abstract The study of prehabilitation and rehabilitation ([p]rehabilitation) to alleviate the sequelae of bladder cancer and its treatment has generated numerous opportunities to improve the quality of life of bladder cancer survivors. The authors conducted a scoping review of randomized clinical trials (RCTs) to identify knowledge gaps in and research directions for (p)rehabilitative support for those affected by bladder cancer. The authors systematically searched six databases and synthesized key findings from RCTs conducted from January 1, 2004, through March 15, 2022, that enrolled participants with bladder cancer, survivors, or caregivers in outpatient (p)rehabilitative programs (e.g., exercise, nutrition, or psychological support). Outcomes were characterized according to eight prespecified, clinically relevant categories. The search retrieved 10,968 records, 27 of which met the inclusion criteria, and 24 described unique RCTs with 2471 enrolled participants. Of 24 interventions, 17 (71%) yielded statistically significant results for the outcome of interest. Only one RCT included a cost‐effectiveness analysis, and only two characterized the efficacy of interventions for caregivers. Of 11 RCTs involving psychological support, eight yielded statistically significant results, as did nine of 11 RCTs with physical exercise interventions, three of four RCTs with educational interventions, three of four RCTs with nutritional support interventions, one of two RCTs with pharmacologic medications, and zero of one RCT with physical therapy. The most promising interventions for inclusion in multimodal, personalized (p)rehabilitation programs included exercise, stress management training, cognitive training, smoking and alcohol cessation counseling, immunonutrition, stoma education, and penile rehabilitation. Further studies of the cost effectiveness and efficacy for caregivers of such interventions are needed. Plain Language Summary In a scoping review of all randomized clinical trials involving prehabilitative or rehabilitative diet, exercise, and psychological support interventions for patients with bladder cancer, survivors, and their caregivers, 17 of 24 (71%) interventions yielded statistically significant improvements in the outcome of interest. Clinicians should consider implementing such interventions for those affected by bladder cancer.
Spinal Injuries and Spine Care in the U.S. Military Health System (2001–Present)
Holly, Kaitlyn E. , Hatton, Malina O. , Bryan, Matthew R , Freedman, Brett A. , Helgeson, Melvin D. , Koehlmoos, Tracey Pérez , Schoenfeld, Andrew J.

Mayo Clinic

Spine | November 1, 2024 | Volume: 50 | Issue: 3 | Pages: 207-215

10.1097/brs.0000000000005199 | PMID 39482276 Get It

Study Design. Literature review. Objective. The goal of this study was to provide a comprehensive outline of spinal injuries that may transpire over the course of military service from traumatic to repetitive stress injuries and chronic sequelae. We considered studies that assessed spinal injuries in combat and non-combat settings as reported in the literature over the last 15 to 20 years. Background. Military service places servicemembers under substantial physical demands, while also exposing them to dangerous, unpredictable environments. As a result, servicemembers are at an increased risk of spinal injuries from combat-related trauma and other causes. They may have different care needs and recovery profiles when compared with civilians with spinal disorders. Materials and Methods. We performed a review of the available literature on spinal injuries and spinal care in the Military Health System from 2001 to the present. Results. The studies discussed in this review were primarily focused on the conflicts in both Iraq and Afghanistan from over 10 years ago and do not fully capture the present-day advancements in military technology that may have an impact on the potential for spinal injuries. The long-term effects of sustained military service and the relative influence of high demand versus sedentary military occupations on the development of spinal disorders remain poorly understood. Given the changing nature of military service, both with respect to the demographic in uniform and the ever-evolving nature of modern combat, we believe that only a long-term prospective observational study dedicated to the surveillance of spinal problems could effectively answer these questions. Conclusion. Further research into the present-day characterization of spinal injuries is warranted given the advancements in both military technology and spine care that have occurred over the last 10 years.
Early adverse outcomes remain challenging to prevent in morbidly obese patients undergoing total hip arthroplasty
Dugdale, Evan M. , Uvodich, Mason E. , Pagnano, Mark W. , Abdel, Matthew P. , Bedard, Nicholas A. , Abdel, Matthew P , Bedard, Nicholas A , Berry, Daniel J.

Mayo Clinic

The Bone & Joint Journal | November 1, 2024 | Volume: 106-B | Issue: 11 | Pages: 1223-1230

10.1302/0301-620x.106b11.bjj-2023-1187.r1 | PMID 39481442 Get It

AimsThe prevalence of obesity is increasing substantially around the world. Elevated BMI increases the risk of complications following total hip arthroplasty (THA). We sought to evaluate trends in BMI and complication rates of obese patients undergoing primary THA over the last 30 years.MethodsThrough our institutional total joint registry, we identified 15,455 primary THAs performed for osteoarthritis from 1990 to 2019. Patients were categorized according to the World Health Organization (WHO) obesity classification and groups were trended over time. Cox proportional hazards regression analysis controlling for confounders was used to investigate the association between year of surgery and two-year risk of any reoperation, any revision, dislocation, periprosthetic joint infection (PJI), venous thromboembolism (VTE), and periprosthetic fracture. Regression was stratified by three separate groups: non-obese; WHO Class I and Class II (BMI 30 to 39 kg/m2); and WHO Class III patients (BMI ≥ 40 kg/m2).ResultsThere was a significant increase in the proportion of all obesity classes from 1990 to 2019, and the BMI values within each WHO class significantly increased over time. Risk of any reoperation did not change over time among non-obese or WHO Class I/II patients, but increased for WHO Class III patients (hazard ratio (HR) 1.04; p = 0.044). Risk of dislocation decreased over time for non-obese (HR 0.96; p < 0.001) and WHO Class I/II (HR 0.96; p = 0.002) patients, but did not change over time for WHO Class III (HR 0.94; p = 0.073) patients. Risks of any revision and PJI did not change over time for any group.ConclusionThe proportion of patients undergoing THA who are obese has increased dramatically at our institution between 1990 and 2019. Despite BMI values increasing within all WHO classes over time, two-year complication risks have remained stable or decreased in WHO Class I/II patients. However, continued efforts will be required to mitigate risks in the heaviest WHO Class III patients.Cite this article: Bone Joint J 2024;106-B(11):1223–1230.
Reduction of soluble PD-L1 by plasma exchange and radiation therapy in patients with refractory melanoma re-sensitizes to immunotherapy.
Orme, Jacob J. , Lingamaneni, Prashanth, Lavoie, Roxane R. , Hirdler, Jacob, Bering, Elizabeth A., Gicobi, Joanina K. , Hsu, Michelle A. , Dale, Heather, Kottschade, Lisa A. , Block, Matthew S. , Markovic, Svetomir, Olivier, Ken, Owen, Dawn , Dronca, Roxana , Packard, Annie T. , Zhang, Henan , Kim, Yohan , Dorr, Maddy, Dizona, Paul, Hirdler, Jacob B. , Hsu, Michelle, Dale, Heather, Childs, Daniel S. , McWilliams, Robert R. , Mansfield, Aaron S. , Markovic, Svetomir N. , Lester, Scott C. , Daniel, J. , Dong, Haidong , Lucien, Fabrice , Winters, Jeffrey L. , Park, Sean S.

Mayo Clinic

No container title available | October 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4542220/v1 Get It

Abstract Introduction: Immune checkpoint inhibitors (ICI) are an essential systemic therapy for advanced melanoma. However, most melanomas develop resistance to ICI. Tumor-derived soluble PD-L1 (sPD-L1) and other soluble immunosuppressive factors drive checkpoint inhibitor resistance and correlate with inferior survival. We previously showed that therapeutic plasma exchange (TPE) removes sPD-L1 from circulation. Thus, we hypothesized that TPE-mediated removal of sPD-L1 and other immunosuppressive factors could overcome immunotherapy resistance in refractory melanoma. Methods: In this clinical trial (NCT04581382), we prospectively enrolled eighteen (18) patients with widely metastatic melanoma with progression despite anti-PD-1 ICI and elevated sPD-L1 by ELISA (≥1.7ng/mL). Each patient received radiotherapy to between one and three metastatic lesions (at least two unirradiated lesions) followed by three TPE sessions on consecutive days and re-challenge with checkpoint inhibitor. The primary safety and efficacy endpoints of the study were adverse events (AEs) and sPD-L1 reduction by TPE, respectively. Secondary endpoints included RECIST-based response in unirradiated lesions and overall survival. Correlative studies included kinetics of sPD-L1 and soluble immonsuppressive factors and dynamics of peripheral immune cell phenotypes. Results: Mean age was 62 (SD 13) and seven of eighteen (39%) were female. Mean baseline sPD-L1 was 26.31 ng/mL (40.01). The treatment was well-tolerated with one (6%) patient with grade 3 and 4 adverse events from a central line infection after TPE. Levels of sPD-L1 were significantly reduced by TPE (mean 80.2% reduction, p<0.0001). Two patients (11.1%) experienced complete response (CR), one (5.6%) partial response, three (16.7%) stable disease, and 12 (66.7%) progressive disease. In one case, immunotherapy was discontinued after two years due to no detectable lesions. Changes in tumor-reactive (TTR) GZMB+/CX3CR1+/CD11ahigh and other peripheral immune cell populations predicted overall survival in this cohort. In addition to sPD-L1, other soluble mediators of ICI resistance were also reduced by TPE and predicted overall survival in this cohort. Summary/Conclusion: sPD-L1 and other soluble immunoregulatory signaling molecules are important mediators of ICI resistance. SBRT and TPE can resensitize ICI-refractory melanoma by removing these factors. Patients with persistently elevated or rapid rebound of sPD-L1 following TPE experienced poor response and overall survival. Serial monitoring of sPD-L1 may predict response to ICI and multiple courses of TPE may be necessary. Our findings may apply in other ICI-resistant cancers with elevated sPD-L1. ClinicalTrials.gov registration: NCT04581382, ReCIPE-M1 (Rescuing Cancer Immunotherapy with Plasma Exchange in Melanoma 1).
Revised Classification of Inner Ear Schwannomas
Lloyd, Simon , Freeman, Simon , Kösling, S., Biggs, Nigel, Gubbels, Samuel P., Hess-Erga, Jeanette , Lohse, Christine M. , Marinelli, John P. , Micco, Riccardo Di , Nassiri, Ashley M. , Scheffler, Jonas , Cayé‐Thomasen, Per , Carlson, Matthew L., Plontke, Stefan K. , Arnoldner, Christoph , Borsetto, Daniele , Koo, Ja‐Won , Rahne, Torsten , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | October 30, 2024 | Volume: 46 | Issue: 1 | Pages: 3-9

10.1097/mao.0000000000004363 | PMID 39473303 Get It

ABSTRACT Over the past two decades, there has been increasing interest in the diagnosis and management of schwannomas of the inner ear including hearing rehabilitation with cochlear implants. However, tumor nomenclature and classification within the literature have been variable and oftentimes cumbersome. The term “intralabyrinthine schwannoma” is in common use when describing these tumors but is a potential source of confusion given that people often use the term “labyrinth” or “labyrinthine” to refer to the vestibular component of the inner ear only (i.e., labyrinthectomy or the translabyrinthine approach). During the Ninth Quadrennial Conference on Vestibular Schwannoma and Other Cerebellopontine Angle Lesions in Bergen, Norway, in May 2023, a multidisciplinary group of conference participants met and discussed issues pertaining to current terminology and classifications to enhance clarity and to reflect recent advances in tumor management and hearing rehabilitation. Although a variety of terms have been previously used to describe inner ear schwannomas, consensus was achieved on the term “inner ear schwannoma (IES)” to describe eighth nerve schwannomas of the cochlea, vestibule, or semicircular canals. Subgroups under this term comprise intravestibular, intracochlear, or intravestibulocochlear inner ear schwannomas (low complexity tumors), inner ear schwannomas with transfundal extension into the internal auditory canal but without modiolar involvement (intermediate complexity tumors), and inner ear schwannomas with transfundal extension with modiolar involvement (high complexity tumors). The details of the recommendations for an updated and simplified tumor nomenclature centered around tumor control and hearing rehabilitation with cochlear implantation are presented.
Diagnostic Accuracy Performance of Fluorescence In Situ Hybridization (FISH) for Biliary Strictures: A Systematic Review and Meta-Analysis
Aggarwal, Manik , Simadibrata, Daniel M., Kipp, Benjamin R. , Fritcher, Emily G. Barr , Schneider, Amber, Cooley, Matthew A. , Gores, Gregory J. , Eaton, John E. , Roberts, Lewis R. , Gores, Gregory J. , Barr Fritcher, Emily G , Eaton, John, Roberts, Lewis R , Prokop, Larry J. , Chandrasekhara, Vinay

Mayo Clinic

Journal of Clinical Medicine | October 28, 2024 | Volume: 13 | Issue: 21 | Pages: 6457

10.3390/jcm13216457 | PMID 39518600 Get It

Background and Aims: This systematic review and meta-analysis aims to compare the performance of UroVysion® FISH based on the different definitions of a positive result used in published literature with the goal of determining the optimal FISH definition for detecting pancreaticobiliary malignancy. Methods: A systematic literature search identified studies from database inception to Sept 2024 that evaluated the diagnostic performance of FISH in determining malignancy among patients with biliary strictures. All thresholds for positive FISH, as defined by the individual study, were included in this review. Subgroup analysis was performed based on the definitions of positive FISH as follows: (1) polysomy only; (2) polysomy, tetrasomy, or trisomy; and (3) polysomy or 9p deletion. Results: Eighteen studies comprising 2516 FISH specimens were analyzed, including 1133 (45.0%) with malignancy. Using a threshold for positivity as defined in individual studies, the overall sensitivity of FISH was 57.6% (95% confidence interval [CI], 49.4–65.4%), and the overall specificity was 87.8% (95% CI, 79.2–93.2%). Subgroup analysis showed that polysomy as the threshold for positive FISH yielded a sensitivity of 49.4% (95% CI, 43.2–55.5%), with an increased specificity of 96.2% (95% CI, 92.7–98.1%), while polysomy + tetrasomy/trisomy as positive FISH resulted in an increased sensitivity of 64.3% (95% CI 55.4–72.2%) but a decreased specificity of 78.9% (95% CI 64.4–88.5%). The addition of 9p deletion to polysomy as the criteria for a positive test resulted in a non-significant increase in sensitivity (54.7% (95% CI 42.4–66.5%) while maintaining specificity (95.1% (95% CI 84.0–98.6%). Conclusions: Based on these findings, polysomy only or polysomy/9p deletion should be considered as the criterion for defining a positive FISH test to improve diagnostic sensitivity while maintaining high specificity.
Inhaled Reliever Therapies for Asthma
Rayner, Daniel , Ferri, Dario , Guyatt, Gordon H, Brignardello‐Petersen, Romina , Foroutan, Farid , Chipps, Bradley E. , Perry, Tamara T. , Oppenheimer, John , Israel, Elliot, Hoyte, Flavia, Rivera‐Spoljaric, Katherine , McCabe, Ellen , Rangel, Susana, Shade, Lindsay , Hall, Lisa , Sue-Wah-Sing, Dia, Melendez, Angel , Orr, H. C., Winders, Tonya , Gardner, Donna D. , Przywara, Kathyrn, Rank, Matthew A. , Chu, Derek K. , Foroutan, Farid , Chu, Derek K , O’Byrne, Paul M. , Sumino, Kaharu , Nyenhuis, Sharmilee Maria , Israel, Elliot , Hoyte, Flavia Cecilia Lega , Press, Valerie G. , Hall, Lisa, Orr, Hilarry, Przywara, Kathyrn, Bacharier, Leonard B. , Mosnaim, Giselle S

Mayo Clinic

JAMA | October 28, 2024 | Volume: 333 | Issue: 2 | Pages: 143

10.1001/jama.2024.22700 | PMID 39465893 Get It

Importance The optimal inhaled reliever therapy for asthma remains unclear. Objective To compare short-acting β agonists (SABA) alone with SABA combined with inhaled corticosteroids (ICS) and with the fast-onset, long-acting β agonist formoterol combined with ICS for asthma. Data Sources The MEDLINE, Embase, and CENTRAL databases were searched from January 1, 2020, to September 27, 2024, without language restrictions. Study Selection Pairs of reviewers independently selected randomized clinical trials evaluating (1) SABA alone, (2) ICS with formoterol, and (3) ICS with SABA (combined or separate inhalers). Data Extraction and Synthesis Two reviewers independently extracted data and assessed risk of bias. Random-effects meta-analyses synthesized outcomes. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to evaluate the certainty of evidence. Main Outcomes and Measures Asthma symptom control (5-item Asthma Control Questionnaire; range, 0-6, lower scores indicate better asthma control; minimum important difference [MID], 0.5 points), asthma-related quality of life (Asthma Quality of Life Questionnaire; range, 1-7, higher scores indicate better quality of life; MID, 0.5 points), risk of severe exacerbations, and risk of serious adverse events. Results A total of 27 randomized clinical trials (N = 50 496 adult and pediatric patients; mean age, 41.0 years; 20 288 male [40%]) were included. Compared with SABA alone, both ICS-containing relievers were associated with fewer severe exacerbations (ICS-formoterol risk ratio [RR], 0.65 [95% CI, 0.60-0.72]; risk difference [RD], −10.3% [95% CI, −11.8% to −8.3%]; ICS-SABA RR, 0.84 [95% CI, 0.73-0.95]; RD, −4.7% [95% CI, −8.0% to −1.5%]) with high certainty. Compared with SABA alone, both ICS-containing relievers were associated with improved asthma control (ICS-formoterol RR improvement [MID] in total score, 1.07 [95% CI, 1.04-1.10]; RD, 4.1% [95% CI, 2.3%-5.9%]; ICS-SABA RR, 1.09 [95% CI, 1.03-1.15]; RD, 5.4% [95% CI, 1.8%-8.5%]) with high certainty. In an indirect comparison with ICS-SABA, ICS-formoterol was associated with fewer severe exacerbations (RR, 0.78 [95% CI, 0.66-0.92]; RD, −5.5% [95% CI, −8.4% to −2.0%]) with moderate certainty. Compared with SABA alone, ICS-formoterol (RD, −0.6% [95% CI, −1.3% to 0%]) was not associated with increased risk of serious adverse events (high certainty) and ICS-SABA (RD, 0% [95% CI, −1.1% to 1.2%]) was not associated with increased risk of serious adverse events (moderate certainty). Conclusions and Relevance In this network meta-analysis of patients with asthma, ICS combined with formoterol and ICS combined with SABA were each associated with reduced asthma exacerbations and improved asthma control compared with SABA alone.